↓ Skip to main content

Dove Medical Press

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy

Overview of attention for article published in Biologics: Targets & Therapy, December 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#42 of 287)
  • High Attention Score compared to outputs of the same age (82nd percentile)

Mentioned by

twitter
1 X user
patent
2 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
107 Mendeley
Title
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Published in
Biologics: Targets & Therapy, December 2018
DOI 10.2147/btt.s114530
Pubmed ID
Authors

Michelle E Keyel, C Patrick Reynolds

Timeline
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 107 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 14 13%
Student > Doctoral Student 10 9%
Researcher 9 8%
Student > Bachelor 9 8%
Student > Master 9 8%
Other 15 14%
Unknown 41 38%
Readers by discipline Count As %
Medicine and Dentistry 21 20%
Biochemistry, Genetics and Molecular Biology 13 12%
Agricultural and Biological Sciences 12 11%
Immunology and Microbiology 3 3%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 10 9%
Unknown 45 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2024.
All research outputs
#3,599,717
of 26,367,306 outputs
Outputs from Biologics: Targets & Therapy
#42
of 287 outputs
Outputs of similar age
#75,089
of 451,266 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 4 outputs
Altmetric has tracked 26,367,306 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 287 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,266 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them